SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Walgreens Boots Alliance, Inc.

SG&A Efficiency: Summit vs. Walgreens Over a Decade

__timestampSummit Therapeutics Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 2014679523817992000000
Thursday, January 1, 2015745424722400000000
Friday, January 1, 20161034586223910000000
Sunday, January 1, 20171698420323813000000
Monday, January 1, 20181618729024694000000
Tuesday, January 1, 20199299233.5423557000000
Wednesday, January 1, 20201923200025436000000
Friday, January 1, 20212361100024586000000
Saturday, January 1, 20222670000027295000000
Sunday, January 1, 20232821500034205000000
Monday, January 1, 202428113000000
Loading chart...

In pursuit of knowledge

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving landscape of corporate finance, understanding a company's efficiency in managing its Selling, General, and Administrative (SG&A) expenses is crucial. This analysis juxtaposes Summit Therapeutics Inc. and Walgreens Boots Alliance, Inc., two giants in their respective fields, over a decade.

From 2014 to 2023, Summit Therapeutics Inc. saw a steady increase in SG&A expenses, peaking at approximately $28 million in 2023, marking a 315% rise from 2014. In contrast, Walgreens Boots Alliance, Inc. consistently reported SG&A expenses in the tens of billions, with a notable 44% increase from 2014 to 2024.

This comparison highlights the stark differences in scale and operational strategies between a pharmaceutical innovator and a retail behemoth. While Summit's growth trajectory is impressive, Walgreens' ability to maintain efficiency at such a large scale is equally commendable. Missing data for Summit in 2024 suggests a need for further analysis.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025